Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05575440 · ClinicalTrials.gov registry record

Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer

A clinical trial of Thyroid Gland Papillary Carcinoma and Thyroid Gland Follicular Carcinoma, sponsored by Mayo Clinic.

Recruiting
Registry status
24
Enrollment target
1
Study location

NCT05575440: Recruiting study of Thyroid Gland Papillary Carcinoma and Thyroid Gland Follicular Carcinoma, sponsored by Mayo Clinic.

NCT05575440 is a study of Thyroid Gland Papillary Carcinoma and Thyroid Gland Follicular Carcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 24 participants, above the 21-participant average among 3 other Thyroid Gland Papillary Carcinoma trials with a reported enrollment target (14% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05575440, a study of Thyroid Gland Papillary Carcinoma and Thyroid Gland Follicular Carcinoma, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
24 participants
Enrollment target
1
Study location

Study Summary

This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites of recurrent or metastatic disease in differentiated thyroid cancer. 18F-TFB PET/CT may accurately detect recurrent and metastatic thyroid cancer lesions, with the potential to provide information for patient management that is better than the current standard of care imaging practices.

Primary Outcome

Descriptive summaries of detected lesions (presence/absence) will include counts and proportions at the patient and lesion level. Overall concordance of these measures across modalities will be estimated using Cohen's kappa with 95% confidence intervals generated by clustered bootstrapping. Per-lesion analysis of detection rates by modality will be performed using cluster-adjusted McNemar's test, accounting for the paired nature of the data (i.e., two scans) and potential within-sample correlati

Conditions Studied

Thyroid Gland Papillary Carcinoma Thyroid Gland Follicular Carcinoma Differentiated Thyroid Gland Carcinoma

Interventions

  • PROCEDURE Computed Tomography
  • PROCEDURE Positron Emission Tomography
  • OTHER Survey Administration
  • RADIATION Fluorine F 18 Tetrafluoroborate

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2022-04-22
Est. Completion 2028-05-01
Mayo Clinic

2,844 total trials

What NCT05575440 shows while recruiting

NCT05575440 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target, above the 21-participant average among 3 other Thyroid Gland Papillary Carcinoma trials with a reported enrollment target (14% higher).

The record links to 3 conditions, with Thyroid Gland Papillary Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Computed Tomography is the first listed.

NCT05575440 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT05575440 about?

NCT05575440 is a clinical study titled "Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer". This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites of recurrent or metastatic disease in differentiated thyroid cancer. 1...

What is the current status of trial NCT05575440?

This trial is currently recruiting. The enrollment target is 24 participants. The study started on 2022-04-22. Estimated completion is 2028-05-01.

What conditions does trial NCT05575440 study?

This clinical trial studies the following conditions: Thyroid Gland Papillary Carcinoma, Thyroid Gland Follicular Carcinoma, Differentiated Thyroid Gland Carcinoma.

What interventions are being tested in trial NCT05575440?

The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Survey Administration (OTHER), Fluorine F 18 Tetrafluoroborate (RADIATION).

Who is sponsoring clinical trial NCT05575440?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05575440 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Thyroid Gland Papillary Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05575440

Source: ClinicalTrials.gov NCT05575440, the US trial registry maintained by the National Library of Medicine. NCT05575440 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.